Advances in developing novel therapeutic strategies for Alzheimer's disease
J Cao, J Hou, J Ping, D Cai - Molecular neurodegeneration, 2018 - Springer
Abstract Alzheimer's Disease (AD), the most prevalent neurodegenerative disease of aging,
affects one in eight older Americans. Nearly all drug treatments tested for AD today have …
affects one in eight older Americans. Nearly all drug treatments tested for AD today have …
Exosomes derived from hypoxia‐preconditioned mesenchymal stromal cells ameliorate cognitive decline by rescuing synaptic dysfunction and regulating …
GH Cui, J Wu, FF Mou, WH Xie, FB Wang… - The FASEB …, 2018 - Wiley Online Library
Administration of exosomes derived from mesenchymal stromal cells (MSCs) could improve
some neurologic conditions by transferring functional biomolecules to recipient cells …
some neurologic conditions by transferring functional biomolecules to recipient cells …
Epidemiology of Alzheimer disease
The global prevalence of dementia has been estimated to be as high as 24 million, and is
predicted to double every 20 years until at least 2040. As the population worldwide …
predicted to double every 20 years until at least 2040. As the population worldwide …
Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration
S Saxena, P Caroni - Neuron, 2011 - cell.com
Neurodegenerative diseases selectively target subpopulations of neurons, leading to the
progressive failure of defined brain systems, but the basis of such selective neuronal …
progressive failure of defined brain systems, but the basis of such selective neuronal …
Protein aggregation diseases: pathogenicity and therapeutic perspectives
A Aguzzi, T O'connor - Nature reviews Drug discovery, 2010 - nature.com
A growing number of diseases seem to be associated with inappropriate deposition of
protein aggregates. Some of these diseases—such as Alzheimer's disease and systemic …
protein aggregates. Some of these diseases—such as Alzheimer's disease and systemic …
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease
The microtubule-associated protein tau is integral to the pathogenesis of Alzheimer's
disease (AD), as well as several related disorders, termed tauopathies, in which tau is …
disease (AD), as well as several related disorders, termed tauopathies, in which tau is …
Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer's …
KR Sadleir, PC Kandalepas, V Buggia-Prévot… - Acta …, 2016 - Springer
Alzheimer's disease (AD) is characterized by amyloid plaques composed of the β-amyloid
(Aβ) peptide surrounded by swollen presynaptic dystrophic neurites consisting of …
(Aβ) peptide surrounded by swollen presynaptic dystrophic neurites consisting of …
Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease
CH Chen, W Zhou, S Liu, Y Deng, F Cai… - International Journal …, 2012 - academic.oup.com
Elevated levels of β-site APP cleaving enzyme 1 (BACE1) were found in the brain of some
sporadic Alzheimer's disease (AD) patients; however, the underlying mechanism is …
sporadic Alzheimer's disease (AD) patients; however, the underlying mechanism is …
Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process
B De Strooper - Physiological reviews, 2010 - journals.physiology.org
Alzheimer disease is characterized by the accumulation of abnormally folded protein
fragments, ie, amyloid beta peptide (Aβ) and tau that precipitate in amyloid plaques and …
fragments, ie, amyloid beta peptide (Aβ) and tau that precipitate in amyloid plaques and …